1. GlycArt Biotechnology AG, Schlieren, Switzerland;
2. Discovery Oncology, Roche Diagnostics GmbH, Penzberg, Germany;
3. Discovery Inflammation, Roche Glycart, Palo Alto, CA;
4. MRC Toxicology Unit, University of Leicester, Leicester, United Kingdom; and
5. Medical Center, University of Groningen, Groningen, The Netherlands